Expression Analysis Announces RNA-SEQ Grant Program
News Feb 21, 2012
EA has announced that it is working with Golden Helix and Illumina to offer three fully-funded grants for RNA-Seq studies and data analysis to support cutting-edge projects that show promise in identifying genetic elements important to enhance the understanding of disease and improve human health.
For the studies selected, Expression Analysis will perform the sequencing and provide primary and secondary data analysis; Golden Helix will provide cloud-based secondary analysis tools and storage, plus end-user tertiary analysis tools; and, Illumina will provide the products required for the study. In all cases, there is no cost to the grant recipients.
RNA-Seq is a cDNA sequencing application that generates a more comprehensive, quantitative and less biased view of the transcriptome when compared to microarray-based technologies.
“RNA sequencing has clear advantages over existing approaches - delivering detection of novel biology not possible using microarrays. The goal of these grants is to introduce researchers to the many benefits of RNA-Seq and to incorporate this method into their research so they can experience its biological advantages first hand,” stated Steve McPhail, CEO of EA.
The informatics challenges associated with NGS-based research are well known, posing a significant barrier to the broad adoption of RNA-seq.
Overcoming these challenges has been a particularly difficult step on the path to realizing the full value of this promising technology.
“Many researchers turn away from RNA-Seq studies simply because the informatics are unmanageable,” said Andy Ferrin, EVP of Business Development and Services at Golden Helix.
Ferrin continued, “We’re excited to work with EA and Illumina on these grants to help three research groups capitalize on the power of RNA-seq technology without this daunting concern.”
Projects should demonstrate strong evidence that the study design and analysis proposed are likely to have the power to detect genetic factors affecting the trait under study.
There will be one grant awarded in each of the following categories:
- Biomarker discovery using whole transcriptome sequencing
- Developmental coding and non-coding RNA expression
- RNA-Seq analysis of FFPE samples
Applications for the grant are due by April 13, 2012 and the awardees will be notified no later than May 15, 2012.
For more information about the program, including application requirements and materials, visit www.ExpressionAnalysis.com/Grant.
New Approach Identifies Important Undiscovered Functions of ProteinsNews
Scientists have developed a new method to discover which surface contacts on proteins are critical for these cellular interactions. The novel approach shows that essential new functions can be uncovered even for well-studied proteins, and has significant implications for therapeutic drug development, which depends heavily on how drugs physically interact with their cellular targets.READ MORE
Single-stranded Origami Technology Drives Drug Delivery Systems and Pharmaceutical Nanofactories ForwardNews
First nanotechnological approach enables the design and replication of complex single-stranded DNA and RNA origami with potential for drug delivery and nanofabrication.READ MORE
Cracking the Code of Coenzyme Q BiosynthesisNews
Coenzyme Q is a vital cog in the body’s energy-producing machinery, a kind of chemical gateway in the conversion of food into cellular fuel. Researchers are developing new tools to shed light on CoQ function, primarily by finding and defining proteins that have a direct link to the chemical. This includes the development of a new multi-omic strategy to identify the global function of an RNA-binding protein that has long been associated with mitochondria and its role in CoQ biosynthesis.READ MORE